velop CME that is persistent despite a fixed-dose monthly therapy [7] . Rescue therapies for such patients with recalcitrant post-radiation CME have not been well described to date.
Aflibercept (Eylea; Regeneron Pharmaceuticals, Inc.) is a fully human, soluble recombinant VEGF receptor decoy that inhibits VEGF isoforms A and B (VEGF-A, VEGF-B) and placental growth factor (PlGF). Preclinical studies have shown that the binding affinity of aflibercept for VEGF-A is higher than native VEGF receptors [10] . The purpose of this study was to assess the efficacy of intravitreal aflibercept as rescue therapy for persistent postradiation CME resistant to prior treatment with IVB.
Methods
Institutional Review Board approval from Wills Eye Hospital was obtained for this retrospective, interventional, case-controlled series. This research adhered to the tenets of the Declaration of Helsinki and was conducted in accordance with regulations set forth by the Health Insurance Portability and Accountability Act. All patients were managed at the Ocular Oncology Service of Wills Eye Hospital, Philadelphia, PA, USA.
The clinical records of all patients with persistent post-radiation CME following iodine-125 plaque radiotherapy for uveal melanoma treated with intravitreal aflibercept were reviewed. Persistent post-radiation CME was defined as increased or stable CMT compared to baseline values despite a minimum of 3 monthly standard-dose (1.25 mg) IVB treatments. For the purpose of this study, change in CMT between baseline and follow-up was classified as decreased (>10% decrease in CMT compared to baseline), stable (within 10% of baseline CMT), or increased (>10% increase in CMT compared to baseline).
The following demographic and clinical features were recorded: age, gender, lens status, past ocular and medical history, Snellen visual acuity, tumor location, tumor diameter, and tumor thickness. Parameters of iodine-125 plaque radiotherapy, including total dose (cGy) and dose rate (cGy/h) to the tumor apex, base, optic disc, and foveola, were noted. Details regarding onset and treatment for post-radiation CME were also recorded.
Five eyes of 5 patients with persistent post-radiation CME were treated with aflibercept and included in the intervention group. All 315 eyes were treated with a minimum of 6 monthly injections of intravitreal aflibercept, with follow-up examinations and spectral domain optical coherence tomography (OCT) performed every 4 weeks. After 6 months, the treatment interval could be adjusted based on clinical response. Outcomes at 6 months and 1 year were then compared with a matched control group comprised of 5 eyes of 5 patients with persistent post-radiation CME treated only with IVB. Controls were matched for baseline tumor features, CMT, visual acuity, the number of prior IVB treatments received, and follow-up interval. Snellen visual acuities were converted to logMAR equivalents for statistical analysis. Using a Student t test analysis (GraphPad Software Inc., La Jolla, CA, USA), a p value <0.05 was considered statistically significant. The primary outcomes measured included change in CMT and visual acuity following treatment with aflibercept.
Results
Baseline features including patient age, gender, race, lens status, visual acuity, CMT in the affected and fellow eye, tumor thickness, tumor diameter, and tumor distance to the foveola were statistically similar between the intervention and control group ( Table 1 ) .
In the intervention group, mean logMAR visual acuity at the time of melanoma diagnosis was 0.19 ± 0.10 (Snellen 20/30). Mean tumor basal diameter was 10.7 mm (median 10, range 6-16) and mean tumor thickness was 3.6 mm (median 3.6, range 2.2-4.7). In the control group, mean logMAR visual acuity at the time of melanoma diagnosis was 0.15 ± 0.26 (Snellen 20/28). Mean tumor basal diameter was 10.9 mm (median 11, range 7-18) and mean tumor thickness was 4.6 mm (median 3.9, range 2.6-9.6). Angiographic or OCT-evident CME, macular ischemia, and epiretinal membrane were not present in any eye at baseline. All patients were phakic throughout the study period.
Details of iodine-125 plaque radiotherapy are summarized in Table 2 . In the intervention group, OCT-evident post-radiation CME occurred at a mean of 23 months (median 14, range . Mean CMT at diagnosis of postradiation CME was 479 ± 123 μm and mean logMAR visual acuity was 0.47 ± 0.08 (Snellen 20/60) in the affected eye. In the control group, OCT-evident post-radiation CME occurred at a mean of 26 months (median 16, range 9-61). Mean CMT at diagnosis of post-radiation CME was 444 ± 71 μm and mean logMAR visual acuity was 0.60 ± 0.39 (Snellen 20/79) in the affected eye.
Treatment outcomes are summarized in Table 3 . In the intervention group, eyes were treated with a mean of 11.6 IVB injections (median 10, range 6-22) over a mean duration of 13 months (median 9, range 8-24). Following treatment with 6 monthly injections of intravitreal aflibercept, mean CMT improved from 463 ± 138 to 289 Compared to the control group, the eyes in the intervention group had comparatively lower CMT (289 ± 68 vs. 374 ± 94 μm, p = 0.10) and better visual acuity (0.32 ± 0.19 vs. 0.56 ± 0.28, p = 0.03) at 6 months. These differences were maintained at 1 year, with lower CMT (289 ± 70 vs. 361 ± 71 μm, p = 0.10) and better visual acuity (0.38 ± 0.21 vs. 0.58 ± 0.18, p = 0.02) in the intervention group. There were no injection-related complications.
Discussion
Plaque radiotherapy is the standard of care for most small or medium-sized choroidal melanomas, providing excellent local tumor control [11] . However, vision loss is common following plaque radiotherapy. In a series of 1,106 patients, Shields et al. [2] reported visual acuity outcomes of 20/200 or worse in up to 68% of patients treated with plaque radiotherapy for uveal melanoma at 10 years, with many of such outcomes attributed to sequelae of radiation retinopathy.
To better address visual acuity loss from CME specifically, recent work has sought to prevent occurrence of post-radiation CME as well as identify patients who may be at risk for CME development. Shah et al. [12] found that the use of IVB (1.25 mg) at 4-month intervals following plaque radiotherapy reduced the rate of OCT-evident CME (26 vs. 40%) and moderate vision loss (15 vs. 28%) in treated versus untreated eyes at 2 years, offering clinicians a possible preventative strategy. Moreover, a recent report identified that eyes with subclinical macular edema (greater than a 10-μm difference in CMT between the affected and fellow eye) at baseline were more likely to develop CME after radiation ( p = 0.005; hazard ratio 1.77), offering clinicians an OCT-based criterion to identify high-risk eyes [4] . Similarly, recent case series have sought to evaluate rescue therapies for persistent CME in eyes in which monthly anti-VEGF therapy fails to achieve CME resolution. Bui et al. [13] reported CMT and visual acuity outcomes in 2 patients with persistent post-radiation CME treated with the Ozurdex ® dexamethasone implant (Allergan, Inc., Troy Hills, NJ, USA). The authors noted sustained anatomic improvement with Ozurdex ® compared to prior IVB and intravitreal triamcinolone treatments, but visual acuity improved in only 1 of 2 eyes. Tarmann et al. [14] also reported outcomes in 4 eyes treated with Ozurdex ® for persistent post-radiation CME despite prior IVB therapy. Similar to the results of Bui et al. [13] , improvement in CMT was noted in all eyes but visual acuity improved in only 2 of 4 eyes. In addition, Finger and Chin [15] reported the efficacy of high-dose (2.0 mg) ranibizumab in treating 10 patients' persistent radiation retinopathy despite monthly, standard-dose ranibizumab, hypothesizing that a higher-dose anti-VEGF blockade may improve treatment response in patients with recalcitrant disease. The authors noted that while 80% of the eyes had a statistically significant improvement in CMT at 1 year, visual acuity remained stable.
The use of aflibercept for post-radiation CME is currently off-label. In this series, we found a statistically significant reduction in CMT ( p = 0.02) and improvement in visual acuity ( p = 0.03) following the use of monthly aflibercept at 6 months, gains that remained statistically significant at 1 year. In contrast, CMT did not improve significantly ( p = 0.49) and visual acuity worsened ( p = 0.09) in the control group at 1 year. Comparing groups, CMT was lower ( p = 0.09) and visual acuity was significantly better ( p = 0.02) in the aflibercept group at 1 year. Differing from the findings of Finger and Chin [15] evaluating high-dose ranibizumab therapy and the series evaluating Ozurdex ® as rescue therapy for persistent post-radiation CME [13] [14] [15] , statistically significant improvement in vision was observed with aflibercept treatment. The precise mechanism for the observed reduction in CMT and improvement in visual acuity with aflibercept compared to IVB is speculative. Aflibercept has been demonstrated to bind VEGF-A with over 100-fold greater affinity than bevacizumab, possibly resulting in a more sustained VEGF-A inhibition [16] [17] [18] . Pharmacokinetic studies have also noted a longer predicted duration of action for aflibercept compared to bevacizumab and ranibizumab [19, 20] . In addition, aflibercept inhibits not only VEGF-A but additional growth factors including VEGF-B and PlGF, which have been implicated in the pathogenesis of cystoid edema in other disease states including diabetic macular edema [16] [17] [18] . PlGF blockade may also have anti-inflammatory effects, as PlGF signaling has been implicated in monocyte chemotaxis and tissue factor (i.e., factor III, thromboplastin, CD142) production [21] . The higher affinity anti-VEGF blockade, longer duration of action, and simultaneous blockade of the PlGF cascade may all contribute to the visual acuity and CMT benefit noted with aflibercept in this series. Lastly, mechanisms of tachyphylaxis, including upregulation of VEGF receptors or metabolic changes altering pharmacokinetics of bevacizumab drug absorption, have been previously described with the use of anti-VEGF agents and could result in a dose-independent reduction in bevacizumab treatment response over time [22] .
In the present study, exudative recurrences did not occur following treatment with aflibercept at a mean final follow-up of 12.8 months. In addition, all patients treated with aflibercept could be transitioned to a "treat and extend" regimen at 6 months, with treatment interval extension ranging from 6 to 13 weeks, potentially reducing treatment burden. Longer follow-up will be necessary to determine if the effect of aflibercept on CMT reduction and visual acuity reduction is maintained. A large cohort study has previously reported loss of at least 5 lines of Snellen visual acuity in up to 33% of patients undergoing plaque radiotherapy for uveal melanoma at 5 years [2] . Patients in the intervention group were followed for a mean of 45 months (3.7 years) from the time of plaque radiotherapy to the final follow-up. Over that time, mean logMAR visual acuity changed from 0.19 (Snellen 20/30) to 0.32 (Snellen 20/42), a loss of approximately 1 line of Snellen visual acuity. In the context of prior work noting significant visual loss following plaque radiotherapy in eyes with uveal melanoma, we believe the visual acuity results of this study are reflective of the improved outcomes that can be achieved after radiotherapy in the anti-VEGF era.
This study has several limitations, including the retrospective nature and the small sample size. In addition, while no statistically significant differences between the intervention and control group were present at baseline, exact matching of a control group was not possible. In addition, follow-up fluorescein angiography after initiation of rescue therapy was not available in all patients, and thus subsequent development of macular ischemia and potential influence on visual acuity outcomes could not be evaluated. However, given the rarity of choroidal melanoma and paucity of information regarding rescue therapy for persistent CME, these results could be relevant and warrant future consideration. Additional studies, including the evaluation of aflibercept in treatment-naïve patients and prospective, randomized trials comparing treatment options would be necessary to clarify best practices.
In conclusion, intravitreal aflibercept was an effective rescue treatment for post-radiation CME in eyes with incomplete response to IVB. Statistically significant improvement in CMT and logMAR visual acuity was observed at 6 months that was maintained at 1-year. Additional follow-up and inclusion of a larger cohort is necessary to further define the role of aflibercept as rescue therapy for persistent post-radiation CME.
